<DOC>
	<DOCNO>NCT01425580</DOCNO>
	<brief_summary>Glucagon-like peptide-1 ( GLP-1 ) naturally occur incretin insulinotropic property . Apart glycemic action , cardiovascular effect GLP-1 recently review . Receptors GLP-1 express rodent human heart acute activation GLP-1 signal show influence e.g . heart rate blood pressure . In knock-out mouse model , GLP-1R-/- mouse exhibit defective cardiovascular contractile response together leave ventricular hypertrophy . GLP-1 improves severe leave ventricular heart failure human suffer myocardial infarction . Hence , demonstrate GLP-1 exerts direct functional effect GLP-1 receptor dependent independent pathway heart . Native GLP-1 extremely short act peptide , half-time breakdown 1-2 minute , feature make unsuitable drug treatment type 2 diabetes . To end , several long-acting GLP-1 analogue , drug treat type 2 diabetes , test purpose . The analogue liraglutide exert effect via native GLP-1 receptor , localize pancreatic β-cells , also human heart . Interestingly , liraglutide demonstrate beneficial effect heart function mouse . Taken together , recent data show GLP-1 stable analogue liraglutide exert beneficial cardiovascular effect . The purpose study determine whether glucagon-like peptide-1 ( GLP-1 ) analogue liraglutide improve heart function ( measure leave ventricle longitudinal function and/or functional reserve rest and/or exercise ) 18 week liraglutide + metformin , compare glimepiride + metformin , use tissue Doppler echocardiography .</brief_summary>
	<brief_title>Liraglutide Heart Failure Type 2 Diabetes</brief_title>
	<detailed_description>The subject attend screen visit ( Visit 1 ) order assess eligibility . If find eligible , subject return Visit 2 within approximately 4 week , Visit 1 , up-titration metformin 1 g BID maximal tolerate dosage metformin ( Run-in period ) . At Visit 2 patient test ; - Heart function rest exercise ECG Stress Test tissue Doppler echocardiography - 24-hour blood pressure - Anthropometric assessment - Symptoms dyspnea fatigue ( score system , classified NYHA ) . - Quality life ( SF 36 ) - Blood test ( venipuncture ) Subsequently thereafter , subject visit 2 randomized receive either liraglutide 1.8 mg s.c. ( initial dose 0.6 mg up-titration 0.6 mg every week , final dose 1.8 mg QD ) glimepiride 4 mg p.o ( initial dose 2 mg , up-titration 1 mg every week , final dose 4 mg QD ) . At Visit 2 , subject supply glucose meter ( Abbot Contour ) instruction use device include regular calibration accord manufacturer 's instruction . Subjects instruct record result self measured plasma glucose ( SMPG ) value meter . Subjects ask monitor 7 point profile glucose curve consecutively three day visit 3 , visit 4 end treatment ( visit 5 ) . SMBG value transfer via computerized system ( Diasend® ) . Visit 3 . Telephone visit . Self-reporting glucose measurement . Visit 4 . Telephone visit . Self-reporting glucose measurement . At week 18 ( Visit 5 ) , subject re-tested : - Heart function rest exercise ECG Stress Test tissue Doppler echocardiography - 24-hour blood pressure - Anthropometric assessment - Symptoms dyspnea fatigue ( score system , classified NYHA ) . - Quality life ( SF 36 ) - Blood test ( venipuncture )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Type 2 diabetes . 2 . Heart Failure , visualize echocardiography , one following ( 2.1 , 2.2 2.3 ) . Ejection Fraction ≤ 50 % . Decreased systolic velocity ( four chamber view ) two , four segment ( Septum , Lateral , Inferior Anterior Wall ) relative decrease velocity 20 % compare normal population . Evidence diastolic dysfunction show abnormal leave ventricular relaxation , filling , diastolic distensibility stiffness . An E/E ' ratio ( ratio early diastolic velocity mitral inflow derive Doppler image myocardial movement derive tissue Doppler imaging ) &gt; 15 consider diagnostic diastolic dysfunction E/E ' ratio &lt; 8 diagnostic absence diastolic heart failure . An increased left atrial size ( &gt; 49 ml/ m2 ) increase left ventricular mass ( &gt; 122 g/m2 woman &gt; 149 g/m2 men ) consider sufficient evidence diastolic dysfunction E/E ' ratio inconclusive . 3 . HbA1c ( accordingly IFCC ) 47 mmol/mol 95 mmol/mol . 4 . If antihypertensive treatment , medication stable , change , last 1 month . 5 . Male female subject , 1880 year age . 6 . Signed informed consent form . 1 . Type 1 diabetes ( autoantibody positive ) . 2 . Any history receive GLP1 analogue dipeptidyl peptidase inhibitor ( DPPIV inhibitor ) glimeperide . 3 . Previous treatment glitazones within 6 month . 4 . Previous treatment sulphonylurea within 3 month . 5 . Previous treatment insulin ( regimen ) within 1 month . 6 . Known severe heart failure , classify NYHA 34 . 7 . Significant ischemic heart disease ( define anginalimited exercise unstable angina ) ; document acute myocardial infarction ( MI ) within previous 8 week . 8 . Active myocarditis ; malfunction artificial heart valve . 9 . Atria fibrillation flutter 10 . History ventricular tachycardia within 3 month study entry ; second thirddegree atrioventricular block . 11 . Implanted pacemaker . 12 . Supine systolic blood pressure &lt; 85 mm Hg &gt; 200 mm Hg . 13 . Primary renal impairment ( creatinine clearance &lt; 30 ml/min ) , creatinine clearance &lt; 60 ml/min treat metformin . 14 . Uncorrected hypokalemia hyperkalemia ( potassium &lt; 3.5 mmol/l &gt; 5.5 mmol/l ) . 15 . Significant anemia ( Hb &lt; 90 g/l ) 16 . Treatment another investigational agent within 30 day study entry , judge investigator . 17 . Severe gastrointestinal disease , include gastroparesis . As judged investigator . 18 . Body mass index ( BMI ) &gt; 40 kg/m2 . 19 . Malignant neoplasm require chemotherapy , surgery , radiation palliative therapy previous 5 year . Patients intraepithelial squamous cell carcinoma skin treat topical 5FU subject basal cell skin cancer allow enter trial . 20 . Females child bear potential pregnant , breastfeed intend become pregnant use adequate contraceptive method ( adequate contraceptive measure require local law practice ) . 21 . Current drug alcohol abuse . 22 . History acute chronic pancreatitis 23 . Subjects consider investigator unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Liraglutide</keyword>
</DOC>